Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Basic Research in Cardiology
Erschienen in: Basic Research in Cardiology 6/2009

01.11.2009 | Original Contribution

Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3β/mTOR signaling pathway

verfasst von: Gabriela Placoná Diniz, Marcela Sorelli Carneiro-Ramos, Maria Luiza Morais Barreto-Chaves

Erschienen in: Basic Research in Cardiology | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Several studies have implicated the renin angiotensin system in the cardiac hypertrophy induced by thyroid hormone. However, whether Angiotensin type 1 receptor (AT1R) is critically required to the development of T3-induced cardiomyocyte hypertrophy as well as whether the intracellular mechanisms that are triggered by AT1R are able to contribute to this hypertrophy model is unknown. To address these questions, we employed a selective small interfering RNA (siRNA, 50 nM) or an AT1R blocker (Losartan, 1 μM) to evaluate the specific role of this receptor in primary cultures of neonatal cardiomyocytes submitted to T3 (10 nM) treatment. The cardiomyocytes transfected with the AT1R siRNA presented reduced mRNA (90%, P < 0.001) and protein (70%, P < 0.001) expression of AT1R. The AT1R silencing and the AT1R blockade totally prevented the T3-induced cardiomyocyte hypertrophy, as evidenced by lower mRNA expression of atrial natriuretic factor (66%, P < 0.01) and skeletal α-actin (170%, P < 0.01) as well as by reduction in protein synthesis (85%, P < 0.001). The cardiomyocytes treated with T3 demonstrated a rapid activation of Akt/GSK-3β/mTOR signaling pathway, which was completely inhibited by the use of PI3K inhibitors (LY294002, 10 μM and Wortmannin, 200 nM). In addition, we demonstrated that the AT1R mediated the T3-induced activation of Akt/GSK-3β/mTOR signaling pathway, since the AT1R silencing and the AT1R blockade attenuated or totally prevented the activation of this signaling pathway. We also reported that local Angiotensin I/II (Ang I/II) levels (120%, P < 0.05) and the AT1R expression (180%, P < 0.05) were rapidly increased by T3 treatment. These data demonstrate for the first time that the AT1R is a critical mediator to the T3-induced cardiomyocyte hypertrophy as well as to the activation of Akt/GSK-3β/mTOR signaling pathway. These results represent a new insight into the mechanism of T3-induced cardiomyocyte hypertrophy, indicating that the Ang I/II-AT1R-Akt/GSK-3β/mTOR pathway corresponds to a potential mediator of the trophic effect exerted by T3 in cardiomyocytes.
Literatur
1.
Araujo AS, Schenkel P, Enzveiler AT, Fernandes TR, Partata WA, Llesuy S, Ribeiro MF, Khaper N, Singal PK, Bello-Klein A (2008) The role of redox signaling in cardiac hypertrophy induced by experimental hyperthyroidism. J Mol Endocrinol 41:423–430CrossRefPubMed
2.
Bader M (2002) Role of the local renin-angiotensin system in cardiac damage: a minireview focussing on transgenic animal models. J Mol Cell Cardiol 34:1455–1462CrossRefPubMed
3.
Baker KM, Aceto JF (1990) Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 259:H610–H618PubMed
4.
Barreto-Chaves ML, Heimann A, Krieger JE (2000) Stimulatory effect of dexamethasone on angiotensin-converting enzyme in neonatal rat cardiac myocytes. Braz J Med Biol Res 33:661–664CrossRefPubMed
5.
Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S, Davis PJ (2005) Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146:2864–2871CrossRefPubMed
6.
Billet S, Aguilar F, Baudry C, Clauser E (2008) Role of angiotensin II AT1 receptor activation in cardiovascular diseases. Kidney Int 74:1379–1384CrossRefPubMed
7.
Carneiro-Ramos MS, Diniz GP, Almeida J, Vieira RL, Pinheiro SV, Santos RA, Barreto-Chaves ML (2007) Cardiac angiotensin II type I and type II receptors are increased in rats submitted to experimental hypothyroidism. J Physiol 583:213–223CrossRefPubMed
8.
Carneiro-Ramos MS, Silva VB, Santos RA, Barreto-Chaves ML (2006) Tissue-specific modulation of angiotensin-converting enzyme (ACE) in hyperthyroidism. Peptides 27:2942–2949CrossRefPubMed
9.
Chandrasekar B, Mummidi S, Claycomb WC, Mestril R, Nemer M (2005) Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J Biol Chem 280:4553–4567CrossRefPubMed
10.
Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM, Ross J (2002) Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 99:12333–12338CrossRefPubMed
11.
D’Amore A, Black MJ, Thomas WG (2005) The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 46:1347–1354CrossRefPubMed
12.
13.
Davis PJ, Leonard JL, Davis FB (2008) Mechanisms of nongenomic actions of thyroid hormone. Front Neuroendocrinol 29:211–218PubMed
14.
15.
16.
Diniz GP, Carneiro-Ramos MS, Barreto-Chaves ML (2007) Angiotensin type 1 (AT1) and type 2 (AT2) receptors mediate the increase in TGF-beta1 in thyroid hormone-induced cardiac hypertrophy. Pflugers Arch 454:75–81CrossRefPubMed
17.
Dorn GWII (2007) The fuzzy logic of physiological cardiac hypertrophy. Hypertension 49:962–970CrossRefPubMed
18.
Dorn GWII, Force T (2005) Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115:527–537PubMed
19.
Dzau VJ (1988) Cardiac renin-angiotensin system. Molecular and functional aspects. Am J Med 84:22–27CrossRefPubMed
20.
Eguchi S, Frank GD, Mifune M, Inagami T (2003) Metalloprotease-dependent ErbB ligand shedding in mediating EGFR transactivation and vascular remodelling. Biochem Soc Trans 31:1198–1202CrossRefPubMed
21.
Fischer P, Hilfiker-Kleiner D (2007) Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res Cardiol 102:279–297CrossRefPubMed
22.
Flusberg DA, Numaguchi Y, Ingber DE (2001) Cooperative control of Akt phosphorylation, bcl-2 expression, and apoptosis by cytoskeletal microfilaments and microtubules in capillary endothelial cells. Mol Biol Cell 12:3087–3094PubMed
23.
Godeny MD, Sayeski PP (2006) ERK1/2 regulates ANG II-dependent cell proliferation via cytoplasmic activation of RSK2 and nuclear activation of elk1. Am J Physiol Cell Physiol 291:C1308–C1317CrossRefPubMed
24.
Golomb E, Abassi ZA, Cuda G, Stylianou M, Panchal VR, Trachewsky D, Keiser HR (1994) Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. Am J Physiol 267:H1496–H1506PubMed
25.
Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW (1997) Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 29:366–373PubMed
26.
Gupta S, Das B, Sen S (2007) Cardiac hypertrophy: mechanisms and therapeutic opportunities. Antioxid Redox Signal 9:623–652CrossRefPubMed
27.
Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S (2007) Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci 112:417–428CrossRefPubMed
28.
Horiuchi M, Akishita M, Dzau VJ (1999) Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33:613–621PubMed
29.
Hu LW, Benvenuti LA, Liberti EA, Carneiro-Ramos MS, Barreto-Chaves ML (2003) Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling. Am J Physiol Regul Integr Comp Physiol 285:R1473–R1480PubMed
30.
Kenessey A, Ojamaa K (2006) Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J Biol Chem 281:20666–20672CrossRefPubMed
31.
Kobori H, Ichihara A, Miyashita Y, Hayashi M, Saruta T (1999) Local renin-angiotensin system contributes to hyperthyroidism-induced cardiac hypertrophy. J Endocrinol 160:43–47CrossRefPubMed
32.
Kobori H, Ichihara A, Suzuki H, Takenaka T, Miyashita Y, Hayashi M, Saruta T (1997) Role of the renin-angiotensin system in cardiac hypertrophy induced in rats by hyperthyroidism. Am J Physiol 273:H593–H599PubMed
33.
Kuzman JA, Gerdes AM, Kobayashi S, Liang Q (2005) Thyroid hormone activates Akt and prevents serum starvation-induced cell death in neonatal rat cardiomyocytes. J Mol Cell Cardiol 39:841–844CrossRefPubMed
34.
Kuzman JA, Vogelsang KA, Thomas TA, Gerdes AM (2005) l-Thyroxine activates Akt signaling in the heart. J Mol Cell Cardiol 39:251–258CrossRefPubMed
35.
Ladenson PW, Bloch KD, Seidman JG (1988) Modulation of atrial natriuretic factor by thyroid hormone: messenger ribonucleic acid and peptide levels in hypothyroid, euthyroid, and hyperthyroid rat atria and ventricles. Endocrinology 123:652–657CrossRefPubMed
36.
Liang F, Webb P, Marimuthu A, Zhang S, Gardner DG (2003) Triiodothyronine increases brain natriuretic peptide (BNP) gene transcription and amplifies endothelin-dependent BNP gene transcription and hypertrophy in neonatal rat ventricular myocytes. J Biol Chem 278:15073–15083CrossRefPubMed
37.
Matsui T, Nagoshi T, Rosenzweig A (2003) Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2:220–223PubMed
38.
Morgan HE, Baker KM (1991) Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation 83:13–25PubMed
39.
Morisco C, Zebrowski D, Condorelli G, Tsichlis P, Vatner SF, Sadoshima J (2000) The Akt-glycogen synthase kinase 3beta pathway regulates transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation in cardiac myocytes. J Biol Chem 275:14466–14475CrossRefPubMed
40.
Moser M (2007) Hypertension treatment guidelines: is it time for an update? J Clin Hypertens 9:9–14
41.
Okumura H, Nagaya N, Itoh T, Okano I, Hino J, Mori K, Tsukamoto Y, Ishibashi-Ueda H, Miwa S, Tambara K, Toyokuni S, Yutani C, Kangawa K (2004) Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation 109:242–248CrossRefPubMed
42.
Oudit GY, Penninger JM (2009) Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 82:250–260CrossRefPubMed
43.
Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH (2004) The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 37:449–471CrossRefPubMed
44.
45.
Senbonmatsu T, Ichihara S, Price E Jr, Gaffney FA, Inagami T (2000) Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest 106:R25–R29CrossRefPubMed
46.
Sugden PH, Fuller SJ, Weiss SC, Clerk A (2008) Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol 153:S137–S153CrossRefPubMed
47.
Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH (2004) The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 37:449–471CrossRefPubMed
48.
Pantos C, Mourouzis I, Markakis K, Tsagoulis N, Panagiotou M, Cokkinos DV (2008) Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats. Basic Res Cardiol 103:308–318CrossRefPubMed
49.
Pantos C, Mourouzis I, Xinaris C, Papadopoulou-Daifoti Z, Cokkinos D (2008) Thyroid hormone and “cardiac metamorphosis”: potential therapeutic implications. Pharmacol Ther 118:277–294CrossRefPubMed
50.
Paradis P, MacLellan WR, Belaguli NS, Schwartz RJ, Schneider MD (1996) Serum response factor mediates AP-1-dependent induction of the skeletal alpha-actin promoter in ventricular myocytes. J Biol Chem 271:10827–10833CrossRefPubMed
51.
Sadoshima J, Izumo S (1993) Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73:413–423PubMed
52.
Schaub MC, Hefti MA, Harder BA, Eppenberger HM (1997) Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes. J Mol Med 75:901–920CrossRefPubMed
53.
Schmidt-Ott UM, Ascheim DD (2006) Thyroid hormone and heart failure. Curr Heart Fail Rep 3:114–119CrossRefPubMed
54.
Skurk C, Izumiya Y, Maatz H, Razeghi P, Shiojima I, Sandri M, Sato K, Zeng L, Schiekofer S, Pimentel D, Lecker S, Taegtmeyer H, Goldberg AL, Walsh K (2005) The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 280:20814–20823CrossRefPubMed
55.
Suzuki H, Motley ED, Frank GD, Utsunomiya H, Eguchi S (2005) Recent progress in signal transduction research of the angiotensin II type-1 receptor: protein kinases, vascular dysfunction and structural requirement. Curr Med Chem Cardiovasc Hematol Agents 3:305–322CrossRefPubMed
56.
Takahashi T, Taniguchi T, Konishi H, Kikkawa U, Ishikawa Y, Yokoyama M (1999) Activation of Akt/protein kinase B after stimulation with angiotensin II in vascular smooth muscle cells. Am J Physiol 276:H1927–H1934PubMed
57.
Tsuzuki S, Matoba T, Eguchi S, Inagami T (1996) Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase. Hypertension 28:916–918PubMed
58.
Tuxworth WJ Jr, Shiraishi H, Moschella PC, Yamane K, McDermott PJ, Kuppuswamy D (2008) Translational activation of 5′-TOP mRNA in pressure overload myocardium. Basic Res Cardiol 103:41–53CrossRefPubMed
59.
Varagic J, Frohlich ED (2002) Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol 34:1435–1442CrossRefPubMed
60.
Wakatsuki T, Schlessinger J, Elson EL (2004) The biochemical response of the heart to hypertension and exercise. Trends Biochem Sci 29:609–617CrossRefPubMed
61.
Wang B, Ouyang J, Xia Z (2006) Effects of triiodo-thyronine on angiotensin-induced cardiomyocyte hypertrophy: reversal of increased beta-myosin heavy chain gene expression. Can J Physiol Pharmacol 84:935–941CrossRefPubMed
62.
Wang J, Paradis P, Aries A, Komati H, Lefebvre C, Wang H, Nemer M (2005) Convergence of protein kinase C and JAK-STAT signaling on transcription factor GATA-4. Mol Cell Biol 25:9829–9844CrossRefPubMed
63.
Wu S, Gao J, Ohlemeyer C, Roos D, Niessen H, Kottgen E, Gessner R (2005) Activation of AP-1 through reactive oxygen species by angiotensin II in rat cardiomyocytes. Free Radic Biol Med 39:1601–1610CrossRefPubMed
64.
Yin G, Yan C, Berk BC (2003) Angiotensin II signaling pathways mediated by tyrosine kinases. Int J Biochem Cell Biol 35:780–783CrossRefPubMed
Metadaten
Titel
Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3β/mTOR signaling pathway
verfasst von
Gabriela Placoná Diniz
Marcela Sorelli Carneiro-Ramos
Maria Luiza Morais Barreto-Chaves
Publikationsdatum
01.11.2009
Verlag
D. Steinkopff-Verlag
Erschienen in
Basic Research in Cardiology / Ausgabe 6/2009
Print ISSN: 0300-8428
Elektronische ISSN: 1435-1803
DOI
https://doi.org/10.1007/s00395-009-0043-1

Weitere Artikel der Ausgabe 6/2009

Basic Research in Cardiology 6/2009 Zur Ausgabe

Original Contribution

The role of transient outward K+ current in electrical remodelling induced by voluntary exercise in female rat hearts

Original Contribution

The cardiac troponin C mutation Leu29Gln found in a patient with hypertrophic cardiomyopathy does not alter contractile parameters in skinned murine myocardium

Original Contribution

Cardiac dysfunction in an animal model of neonatal asphyxia is associated with increased degradation of MLC1 by MMP-2

Original Contribution

Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia

Original Contribution

Proliferation of neonatal cardiomyocytes by connexin43 knockdown via synergistic inactivation of p38 MAPK and increased expression of FGF1

Original Contribution

Obesity induced-insulin resistance causes endothelial dysfunction without reducing the vascular response to hindlimb ischemia

Neu im Fachgebiet Kardiologie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise